Computational inference of cancer-specific vulnerabilities in clinical samples
Tóm tắt
Systematic in vitro loss-of-function screens provide valuable resources that can facilitate the discovery of drugs targeting cancer vulnerabilities. We develop a deep learning-based method to predict tumor-specific vulnerabilities in patient samples by leveraging a wealth of in vitro screening data. Acquired dependencies of tumors are inferred in cases in which one allele is disrupted by inactivating mutations or in association with oncogenic mutations. Nucleocytoplasmic transport by Ran GTPase is identified as a common vulnerability in Her2-positive breast cancers. Vulnerability to loss of Ku70/80 is predicted for tumors that are defective in homologous recombination and rely on nonhomologous end joining for DNA repair. Our experimental validation for Ran, Ku70/80, and a proteasome subunit using patient-derived cells shows that they can be targeted specifically in particular tumors that are predicted to be dependent on them. This approach can be applied to facilitate the development of precision therapeutic targets for different tumors.
Tài liệu tham khảo
Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515–26.
Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096–101.
Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164:293–309.
Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564–576.e16.
McDonald ER, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell. 2017;170:577–592.e10.
Wang T, Yu H, Hughes NW, Liu B, Kendirli A, Klein K, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell. 2017;168:890–903.e15.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537–42.
McFarland JM, Ho ZV, Kugener G, Dempster JM, Montgomery PG, Bryan JG, et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018;9:4610.
Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779–84.
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature. 2019;568(7753):511–6.
Kim K, Yang W, Lee KS, Bang H, Jang K, Kim SC, et al. Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes. Nucleic Acids Res. 2015;43:5716–29 Available from: http://nar.oxfordjournals.org/lookup/doi/10.1093/nar/gkv532.
Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37:382–90.
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Jang K, Kim K, Cho A, Lee I, Choi JK. Network perturbation by recurrent regulatory variants in cancer. PLoS Comput Biol. 2017;13:e1005449 Kann MG, editor. Public Library of Science.
Hart T, Moffat J. BAGEL: a computational framework for identifying essential genes from pooled library screens. BMC Bioinformatics. 2016;17:164.
Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012;2:172–89.
Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128. https://doi.org/10.1186/1471-2105-14-128. Published 2013 Apr 15.
Eisenberg E, Levanon EY. Human housekeeping genes, revisited [published correction appears in Trends Genet. 2014 Mar;30(3):119–20]. Trends Genet. 2013;29(10):569–74. https://doi.org/10.1016/j.tig.2013.05.010.
Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol. 2014;10:733.
Xia F, Lee CW, Altieri DC. Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res. 2008;68:1826–33.
Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, et al. Cancer vulnerabilities unveiled by genomic loss. Cell. 2012;150(4):842–54.
Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077–80.
O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18:613–23 Nature Publishing Group.
Ly TK, Wang J, Pereira R, Rojas KS, Peng X, Feng Q, et al. Activation of the ran GTPase is subject to growth factor regulation and can give rise to cellular transformation. J Biol Chem. 2010;285(8):5815–26.
Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell. 2006;22(4):511–9.
Lee KY, Im J-S, Shibata E, Dutta A. ASF1a promotes non-homologous end joining repair by facilitating phosphorylation of MDC1 by ATM at double-strand breaks. Mol Cell. 2017;68:61–75.e5 Elsevier.
Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014;30(8):326–39.
Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014;4(5):592–605.
Jung J, Jang K, Ju JM, Lee E, Lee JW, Kim HJ, et al. Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. Cancer Lett. 2018;428:127–138.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
Han W, Lo H-W. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012;318:124–34.
Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, Rodemann HP. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett. 2010;584:3878–84.
Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999;13:2633–8.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. https://doi.org/10.1038/nature03445.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.
Gurley KE, Kemp CJ. Synthetic lethality between mutation in Atm and DNA-PK (cs) during murine embryogenesis. Curr Biol. 2001;11:191–4 Elsevier.
Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med. 2013;5(189):189ra78.
Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Favera R, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. BioMed Cent; 2006;7:S7.
Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326–30.
Bergstra J, Breuleux O, Bastien FF, Lamblin P, Pascanu R, Desjardins G, et al. Theano: a CPU and GPU math compiler in Python. Proc 9th Python Sci Conf (SCIPY 2010). 2010;.
Erhan D, Courville A, Vincent P. Why does unsupervised pre-training help deep learning? J Mach Learn Res. 2010;11:625–60.
Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B Stat Methodol. 2005;67:301–20.
Sutskever I, Martens J, Dahl GE, Hinton GE. On the importance of initialization and momentum in deep learning. Jmlr W&Cp. 2013;28:1139–47.
Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22.
Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F, Chang C-C, et al. Misc functions of the Department of Statistics, Probability Theory Group, TU Wien. R Packag. version 1.6–2. 2015. https://cran.r-project.org/web/packages/e1071/index.html.
Venables WN, Ripley BD. Modern applied statistics with S Fourth edition by. World; 2002.
Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–83.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. https://doi.org/10.1126/science.1235122.
Jang K, Park MJ, Park JS, Hwangbo H, Sung MK, Kim S, Jung J, Lee JW, Ahn S-Y, Chang S, Choi JK. Computational inference of cancer-specific vulnerabilities in clinical samples. GitHub. http://github.com/kaistomics/DeepDependency (2020).
Jang K, Park MJ, Park JS, Hwangbo H, Sung MK, Kim S, Jung J, Lee JW, Ahn S-Y, Chang S, Choi JK. Computational inference of cancer-specific vulnerabilities in clinical samples. Zenodo. https://doi.org/10.5281/zenodo.3885013 (2020).